Evopoint Biosciences Inc.
2 clinical trials · 2 recruiting · INDUSTRY
Trials by Evopoint Biosciences Inc.
RECRUITINGPhase 1 / Phase 2NCT06702995
Study of XNW5004 Tablet in Combination With Enzalutamide in Subjects With Metastatic Castration-Resistant Prostate...
In this phase Ib/II study, participants with metastatic castration-resistant prostate cancer (mCRPC) who failed prior novel hormone therapy will be treated with XNW5004 in...
Sponsor: Evopoint Biosciences Inc.Enrolling: 3072 locations
Metastatic Castrate-Resistant Prostate CancermCRPC (Metastatic Castration-resistant Prostate Cancer)
RECRUITINGPhase 1 / Phase 2NCT06799637
Study of XNW28012 in Subjects with Advanced Solid Tumors Who Failed Standard Treatments
This is an open-label, dose escalation, multicenter, phase 1, first-in-human study of XNW28012 in subjects with advanced solid tumors who have failed current standard anti-tumor...
Sponsor: Evopoint Biosciences Inc.Enrolling: 20020 locations
Advanced Solid TumorsPancreatic CarcinomaOvarian Cancer+1